The spine and carina as a surrogate for target registration in cone-beam CT imaging verification in locally advanced lung cancer radiotherapy
, und
22. März 2023
Über diesen Artikel
Artikel-Kategorie: Research Article
Online veröffentlicht: 22. März 2023
Seitenbereich: 86 - 94
Eingereicht: 08. Mai 2022
Akzeptiert: 19. Okt. 2022
DOI: https://doi.org/10.2478/raon-2022-0048
Schlüsselwörter
© 2023 Jasna But-Hadzic, Karmen Strljic, Valerija Zager Marcius, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Figure 1
![Automatic clip box carina registration with manual alignment check. Target contours (gross tumour volume [GTV] inner contour, planning target volume [PTV] outer contour) are imported for target registration.](https://sciendo-parsed.s3.eu-central-1.amazonaws.com/647356744e662f30ba53ab78/j_raon-2022-0048_fig_001.jpg?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Credential=AKIA6AP2G7AKOUXAVR44%2F20250911%2Feu-central-1%2Fs3%2Faws4_request&X-Amz-Date=20250911T062431Z&X-Amz-Expires=3600&X-Amz-Signature=e7f0175fc860554b105e28e20891f840ed9ee31d954321159839559dcf275ecd&X-Amz-SignedHeaders=host&x-amz-checksum-mode=ENABLED&x-id=GetObject)
Figure 2

Spine/target registration deviation according to tumour location
0.71 | 1.77 | 1.18 | 3.91 | 1.12 | 1.32 | NS | |||
0.76 | 1.77 | 1.53 | 2.41 | NS | 1.41 | 1.86 | |||
1.47 | 1.55 | NS | 2.59 | 2.32 | NS | 1.35 | 1.45 | NS | |
1.94 | 1.27 | NS | 2.29 | 3.14 | NS | 1.29 | 1.09 | NS |
Mean set-up deviation difference (DD) comparison according to spine/target vs_ carina/target registration
1.28 | 0.90 | 0.38 | NS | 2.65 | 1.80 | 0.85 | NS | 1.20 | 1.43 | -0.23 | NS | |
1.30 | 1.08 | 0.22 | NS | 2.03 | 1.53 | 0.50 | NS | 1.68 | 1.10 | 0.58 | ||
1.48 | 1.08 | 0.4 | NS | 2.38 | 1.65 | 0.73 | 1.38 | 1.38 | 0 | NS | ||
1.53 | 1.05 | 0.48 | NS | 2.73 | 2.15 | 0.58 | NS | 1.2 | 1.43 | -0.23 | NS | |
1.39 | 1.03 | 0.37 | 2.44 | 1.78 | 0.66 | 1.36 | 1.33 | 0.03 | NS |
Patients, disease, and treatment characteristics
Gender | Female | 16 (40 %) |
Male | 24 (60 %) | |
Age (years) | Median (range) | 67 (53–81) |
RUL | 15 (37.5%) | |
RML | 3 (7.5%) | |
Tumour location* | RLL | 7 (17.5%) |
LUL | 8 (20%) | |
LLL | 8 (20%) | |
Central (C)/ | C | 17 (42.5%) |
peripheral (P) tumour location** | P | 22 (55%) |
Histology | NSCLC | 31 (77.5%) |
SCLC | 9 (22.5%) | |
De novo lung cancer | 32 (80%) | |
Local progression | 1 (2.5%) | |
Disease treated | Local recurrence reirradiation | 2 (5%) |
Regional recurrence | 1 (2.5%) | |
Locoregional recurrence reirradiation | 4 (10%) | |
Concurrent chemotherapy | 13 (32.5%) | |
Systemic treatment | Sequential chemotherapy | 16 (40%) |
Target therapy | 1 (2.5%) | |
None | 10 (25%) | |
T0 | 1 (2.5%) | |
T1 | 4 (10%) | |
Tumour (T) stage | T2 | 14 (35%) |
T3 | 8 (20%) | |
T4 | 13 (32.5%) | |
N0 | 9 (22.5%) | |
Lymph nodes (N) | N1 | 1 (2.5%) |
stage | N2 | 14 (35%) |
N3 | 16 (40%) | |
Fractionation | Conventional | 37 (92.5%) |
Hypofractionation | 3 (7.5%) | |
Radiation technique | VMAT | 40 (100%) |
Carina/target registration deviation according to tumour location
0.65 | 1.14 | NS | 1.65 | 2.00 | NS | 1.06 | 1.77 | NS | |
0.53 | 1.55 | 1.18 | 1.86 | 0.82 | 1.32 | NS | |||
0.71 | 1.41 | 1.00 | 2.23 | 0.88 | 1.77 | NS | |||
1.00 | 1.14 | NS | 0.94 | 3.14 | 0.88 | 1.82 | NS |